Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research note on Wednesday, February 26th.

Minerva Neurosciences Trading Up 4.5 %

NASDAQ NERV opened at $1.63 on Tuesday. Minerva Neurosciences has a 52 week low of $1.42 and a 52 week high of $3.69. The stock has a market cap of $11.40 million, a price-to-earnings ratio of -3.70 and a beta of 0.10. The company has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $2.28.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.49. As a group, equities research analysts expect that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of Minerva Neurosciences

A hedge fund recently raised its stake in Minerva Neurosciences stock. Citadel Advisors LLC lifted its stake in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,764 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. Citadel Advisors LLC owned 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the Securities and Exchange Commission. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.